64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)
Evaluation of 64Cu-ATSM PET/CT in Predicting Neo Adjuvant Treatment Response in Locally Advanced Rectum Cancer
Sponsor: Fondation ARC
A PHASE2 clinical study on Rectal Cancer, this trial is ongoing. The trial is conducted by Fondation ARC and has accumulated 10 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Mar 2026 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2025 — Mar 2026 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Sep 2022 — Apr 2024 [monthly]
Recruiting PHASE2
-
Jun 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jun 2019 — Mar 2020 [monthly]
Recruiting PHASE2
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fondation ARC
- Institut Cancerologie de l'Ouest
For direct contact, visit the study record on ClinicalTrials.gov .